<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837629</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-RSI-SYM-2006/1</org_study_id>
    <nct_id>NCT00837629</nct_id>
  </id_info>
  <brief_title>Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>An Open-label Non-interventional Evaluation of Efficacy of Symbicort® Forte Turbuhaler 320/9 µg (Budesonide / Formoterol) and Symbicort® Turbuhaler® 160/4,5 µg (Budesonide / Formoterol)in Functional Status Improvement of Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional study is to analyse the therapeutic effectiveness in patients with
      severe COPD following a generally accepted 12-week treatment period with Symbicort
      Turbuhaler, which could anyhow be shortened or extended at physician's discretion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in overall Clinical COPD Questionnaire (CCQ) score</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physicians' global clinical impression of the treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of smoking habits</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">743</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients (outpatient or hospitalised) in whom Symbicort Turbuhaler is indicated according
        to the current Summary of product characteristics (SPC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non pregnant female

          -  COPD with persistent symptoms in spite of regular bronchodilator therapy

          -  Naive or fixed combination treated patients including patients already on Symbicort
             Turbuhaler

        Exclusion Criteria:

          -  Hypersensitivity to budesonide, formoterol or inhaled lactose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matjaz Flezar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Golnik Hospital</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2009</study_first_submitted>
  <study_first_submitted_qc>February 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2009</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Meta Jeras, Mr Ph, Regulatory and Medical Affairs Manager</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Symbicort Turbuhaler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

